Today is the inaugural ASTech Bi-annual Conference, hosted at Trajan Scientific and Medical's Global Corporate Headquarters in Melbourne, Australia.
The ASTech Bi-annual conference provides a forum for Work Program teams to present their progress and research findings to ASTech Investigators, Steering Committee, and industry stakeholders.
An Industry and Commercialization Unit is also run by Trajan as part of the conference for ASTech Participants, Postdoctoral Fellows and HDR Candidates, which is credited towards the Graduate Certificate in Research at University of Tasmania.
Photo (L-R): Harry Ritchie, Marc Neglia, Pavel Nesterenko, Dario Arrua, Elpis Barons, James Chan, Elisenda Fornells Vernet, Brett Paull, Masoomeh Tehrani-Rokh, Sara Thomas, Rick Barber, Antonia Armitage, Neeraj Verma, Rosanne Guijt, Angela Tomisich, Andrew Gooley, Stephen Tomisich, Hans-Jurgen Wirth, Florian Lapierre, Emily Hilder, Paul Haddad, Michael Breadmore, Mike Bailey, Rob Shellie, Glenn Clivaz, Ricardo Neto, Kannan Ragunathan.
Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.
Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.